Program
zilucoplan
Also written as “Zilucoplan”, “zilucoplan (RA101495)” and “Zilucoplan (RA101495)”.
Its studies are mostly in Myasthenia Gravis · Hemoglobinuria, Paroxysmal · Muscular Diseases · COVID-19, led by 2 companies.
Drug pageZilucoplan: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCBits history only | 133 open or running | phase 3since Oct 2, 2019 | Jan 20, 2017 | Mar 23, 2027phase 1 · NCT06961747 |
| Amgen | 10 open or running | phase 3since Oct 14, 2020 | Oct 14, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2017Named zilucoplanINNProposed as its International Nonproprietary Name in WHO's List 118
- Oct 14, 2020First study: phase 3 study in COVID-19First studyNCT04590586 · 515 enrolled · United States, Argentina, Brazil and more
TargetBeta
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
The one study Amgen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04590586COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Aug 3, 2021 | 515 |
How it is read
Names in the registry
- “Zilucoplan”, 6 entries
- “zilucoplan (RA101495)”, 4 entries
- “Zilucoplan (RA101495)”, 3 entries
- “zilucoplan”, 1 entry
Conditions, from the studies’ own filings
- Myasthenia Gravis, 7 studies
- Hemoglobinuria, Paroxysmal, 3 studies
- Muscular Diseases, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.